Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert L Murphy

Showing results (61-70 of 176) with videos related to

Pageof 18
Sort By:
AIDS (London, England)|April 13, 2004
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up studyCharles Hicks, Martin S King, Roy M Gulick, et al.
AIDS Care|February 5, 2011
Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362Susan E Cohn, Hongyu Jiang, J Allen McCutchan, et al.
AIDS (London, England)|November 16, 2010
Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccineLaura Papagno, Galit Alter, Lambert Assoumou, et al.
AIDS (London, England)|June 27, 2008
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)Brigitte Autran, Robert L Murphy, Dominique Costagliola, et al.
The Journal of Infectious Diseases|February 6, 2020
Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or RaltegravirTodd T Brown, Carlee Moser, Judith S Currier, et al.
The Journal of Infectious Diseases|May 8, 2015
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or RaltegravirTodd T Brown, Carlee Moser, Judith S Currier, et al.
Infectious Agents and Cancer|November 15, 2014
High-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytologyJonah Musa, Chad Achenbach, Babafemi Taiwo, et al.
The Journal of Infectious Diseases|July 23, 2002
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)Arlene S Pereira, Laura M Smeaton, John G Gerber, et al.
HIV Clinical Trials|January 25, 2008
Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patientsRobert L Murphy, Barbara A da Silva, Charles B Hicks, et al.
The Journal of Antimicrobial Chemotherapy|March 27, 2009
Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimenMariana Gerschenson, Courtney Kim, Baiba Berzins, et al.
Pageof 18

Showing results (61-70 of 176) with videos related to

Sort By:
Pageof 18
AIDS (London, England)|April 13, 2004
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up studyCharles Hicks, Martin S King, Roy M Gulick, et al.
AIDS Care|February 5, 2011
Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362Susan E Cohn, Hongyu Jiang, J Allen McCutchan, et al.
AIDS (London, England)|November 16, 2010
Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccineLaura Papagno, Galit Alter, Lambert Assoumou, et al.
AIDS (London, England)|June 27, 2008
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)Brigitte Autran, Robert L Murphy, Dominique Costagliola, et al.
The Journal of Infectious Diseases|February 6, 2020
Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or RaltegravirTodd T Brown, Carlee Moser, Judith S Currier, et al.
The Journal of Infectious Diseases|May 8, 2015
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or RaltegravirTodd T Brown, Carlee Moser, Judith S Currier, et al.
Infectious Agents and Cancer|November 15, 2014
High-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytologyJonah Musa, Chad Achenbach, Babafemi Taiwo, et al.
The Journal of Infectious Diseases|July 23, 2002
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)Arlene S Pereira, Laura M Smeaton, John G Gerber, et al.
HIV Clinical Trials|January 25, 2008
Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patientsRobert L Murphy, Barbara A da Silva, Charles B Hicks, et al.
The Journal of Antimicrobial Chemotherapy|March 27, 2009
Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimenMariana Gerschenson, Courtney Kim, Baiba Berzins, et al.
Pageof 18